• breast cancer - triple negative
• es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
• es-BC - TNBC - NA - all population 5
• es-BC - TNBC - NA - PDL1 positive 1
• es-BC - Triple negatif (TNBC) - 1st line (L1)
• mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
• mBC - Triple negative (TNBC) - 1st Line (L1) 1
• mBC - TNBC - L1 - all population 7
• mBC - TNBC - L1 - PDL1 positive 4
• mBC-Triple negative (TNBC) - 2nd Line (L2) 3
• mBC - TNBC - L2 - all population 2
• mBC - TNBC - L2 - PDL1 positive 2

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
• durvalumab based treatment
• durvalumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;